Geron Corp
Closed
SectorHealthcare
1.4 -1.41
Overview
Share price change
24h
Min
1.3599999999999999
Max
1.41
Income | 25M -3.6M |
|---|---|
Sales | 3.8M 52M |
EPS | -0.005 |
Profit margin | -7.026 |
Employees | 258 |
EBITDA | 24M 90K |
Recommendations | Buy |
|---|---|
12 Months Forecast | +130.5% upside |
Next Earnings | 5 Aug 2026 |
|---|
Market Cap | -114M 892M |
|---|---|
Previous open | 2.81 |
Previous close | 1.4 |
Geron Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Price Target
By TipRanks
130.5% upside
12 Months Forecast
Average 3.25 USD 130.5%
High 5 USD
Low 1 USD
Based on 5 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
